Back to News
Jan 12, 2026 8:00 PM

Ribo Life Enters Hong Kong Biotech Fast Lane After Strong Debut

Shares of China's leading developer of small interfering RNA therapeutics, or siRNA, jumped 42% in their Friday debut, and continued to climb on Monday

Hong Kong investors can now trade in their first mRNA concept stock, following the strong trading debut for Suzhou Ribo Life Science Co. Ltd. (6938.HK), China's leader in the field for small interfering RNA therapeutics, or siRNA.

Ribo Life's stock jumped 42% to close at HK$82.10 on its first trading day last Friday, and continued to rise on Monday, after the company raised about HK$1.7 billion ($218 million) by selling 31.6 million shares for HK$57.97 each. The listing attracted 11 cornerstone investors, including Taikang Life and Da Cheng International Management, which collectively subscribed to 13.4 million shares, or about 42.5% of the amount sold.

The listing was Hong Kong's first by a drug company in 2026, and comes into one of the city's hottest IPO markets in years, with Ribo among 11 new stocks set to debut in the ...